​

Applied Therapeutics (APLT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

APLT Stock Forecast

Applied Therapeutics (APLT) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $4.50, with a high of $5.00 and a low of $4.00. This represents a 243.51% increase from the last price of $1.31.

- $1 $2 $3 $4 $5 $6 $7 $8 $9 High: $5 Avg: $4.5 Low: $4 Last Closed Price: $1.31

APLT Stock Rating

Applied Therapeutics stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (54.55%), 4 Hold (36.36%), 1 Sell (9.09%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 1 4 6 Strong Sell Sell Hold Buy Strong Buy

APLT Price Target Upside V Benchmarks

TypeNameUpside
StockApplied Therapeutics243.51%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$4.50
Last Closing Price$1.31$1.31$1.31
Upside/Downside--243.51%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25-22--4
Sep, 25-22--4
Aug, 25-22--4
Jul, 25-22--4
Jun, 25-22--4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 29, 2024Brian SkorneyRobert W. Baird$5.00$9.42-46.92%281.68%
Nov 29, 2024Brian AbrahamsRBC Capital$4.00$9.42-57.54%205.34%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 29, 2024RBC CapitalOutperformSector Performdowngrade
Sep 19, 2024CitigroupBuyBuyhold
Aug 27, 2024CitigroupBuyBuyhold
Jul 31, 2024William BlairOutperforminitialise
Mar 25, 2024RBC CapitalOutperforminitialise
Aug 16, 2022Morgan StanleyOverweightOverweighthold

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.42$-0.76----
Avg Forecast$-1.43$-1.40$-0.59$-0.28$-0.43$-0.30
High Forecast$-0.33$-1.37$-0.55$-0.17$-0.10$-0.07
Low Forecast$-3.14$-1.43$-0.62$-0.39$-0.94$-0.66
Surprise %-0.70%-45.71%----

Revenue Forecast

$0 $50M $100M $150M $200M $250M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$9.99M$455.00K----
Avg Forecast$10.67M$520.67K$13.02M$57.75M$61.04M$126.62M
High Forecast$20.48M$640.82K$20.03M$110.83M$117.13M$242.99M
Low Forecast$4.37M$400.51K$6.00M$23.63M$24.97M$51.80M
Surprise %-6.34%-12.61%----

Net Income Forecast

$-300M $-240M $-180M $-120M $-60M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-119.76M$-105.62M----
Avg Forecast$-119.76M$-117.94M$-49.44M$-23.54M$-36.23M$-25.27M
High Forecast$-27.97M$-115.13M$-46.25M$-14.36M$-8.40M$-5.86M
Low Forecast$-264.79M$-120.75M$-52.64M$-32.72M$-79.50M$-55.47M
Surprise %--10.44%----

APLT Forecast FAQ

Is Applied Therapeutics stock a buy?

Applied Therapeutics stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 4 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Applied Therapeutics is a favorable investment for most analysts.

What is Applied Therapeutics's price target?

Applied Therapeutics's price target, set by 11 Wall Street analysts, averages $4.5 over the next 12 months. The price target range spans from $4 at the low end to $5 at the high end, suggesting a potential 243.51% change from the previous closing price of $1.31.

How does Applied Therapeutics stock forecast compare to its benchmarks?

Applied Therapeutics's stock forecast shows a 243.51% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Applied Therapeutics over the past three months?

  • October 2025: 0% Strong Buy, 50.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 0% Strong Buy, 50.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 0% Strong Buy, 50.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.

What is Applied Therapeutics’s EPS forecast?

Applied Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.59, marking a -22.37% decrease from the reported $-0.76 in 2024. Estimates for the following years are $-0.28 in 2026, $-0.43 in 2027, and $-0.3 in 2028.

What is Applied Therapeutics’s revenue forecast?

Applied Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $13.02M, reflecting a 2760.68% increase from the reported $455K in 2024. The forecast for 2026 is $57.75M, followed by $61.04M for 2027, and $126.62M for 2028.

What is Applied Therapeutics’s net income forecast?

Applied Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-49.445M, representing a -53.19% decrease from the reported $-106M in 2024. Projections indicate $-23.54M in 2026, $-36.225M in 2027, and $-25.273M in 2028.